Zacks Investment Research cut shares of ProQR Therapeutics N.V. (NASDAQ:PRQR) from a buy rating to a hold rating in a research report released on Tuesday morning.

According to Zacks, “ProQR Therapeutics B.V. is a biotech company. It is engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis (CF). The Company’s lead product candidate includes QR-010, a RNA-based oligonucleotide for the treatment of cystic fibrosis. ProQR Therapeutics B.V. is headquartered in Leiden, the Netherlands. “

Separately, HC Wainwright reissued a buy rating and set a $40.00 price target on shares of ProQR Therapeutics N.V. in a research note on Tuesday, June 20th. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. The company has an average rating of Hold and an average target price of $14.15.

Shares of ProQR Therapeutics N.V. (NASDAQ:PRQR) opened at 5.30 on Tuesday. The company’s market capitalization is $127.76 million. ProQR Therapeutics N.V. has a one year low of $3.65 and a one year high of $8.70. The firm’s 50-day moving average price is $5.02 and its 200 day moving average price is $4.88.

ILLEGAL ACTIVITY WARNING: This news story was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another domain, it was copied illegally and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://www.watchlistnews.com/zacks-investment-research-downgrades-proqr-therapeutics-n-v-prqr-to-hold/1537597.html.

Several institutional investors have recently modified their holdings of the company. Sphera Funds Management LTD. increased its position in shares of ProQR Therapeutics N.V. by 65.0% in the first quarter. Sphera Funds Management LTD. now owns 330,000 shares of the biopharmaceutical company’s stock worth $1,650,000 after buying an additional 130,000 shares during the period. Artal Group S.A. increased its position in shares of ProQR Therapeutics N.V. by 25.0% in the second quarter. Artal Group S.A. now owns 500,000 shares of the biopharmaceutical company’s stock worth $2,600,000 after buying an additional 100,000 shares during the period. Janus Henderson Group PLC bought a new position in shares of ProQR Therapeutics N.V. during the second quarter worth about $2,028,000. Finally, Redmile Group LLC increased its position in shares of ProQR Therapeutics N.V. by 2.8% in the second quarter. Redmile Group LLC now owns 1,596,275 shares of the biopharmaceutical company’s stock worth $8,301,000 after buying an additional 43,050 shares during the period. Institutional investors own 35.93% of the company’s stock.

About ProQR Therapeutics N.V.

ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Utilizing its RNA repair technologies, the Company is developing a pipeline in severe genetic disorders, such as cystic fibrosis (CF) and Leber’s congenital amaurosis (LCA).

Get a free copy of the Zacks research report on ProQR Therapeutics N.V. (PRQR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for ProQR Therapeutics N.V. (NASDAQ:PRQR)

Receive News & Ratings for ProQR Therapeutics N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics N.V. and related companies with Analyst Ratings Network's FREE daily email newsletter.